Posts

Judge Grants Hearing for Opposition to DEA Proposal to Criminalize 5 More Psychedelics
PolicyBiotech companies and researchers opposed to five more tryptamines becoming schedule 1 controlled substances will present their case this spring.

DEA Proposes Adding 5 More Psychedelics to Schedule 1 Controlled Substances
PolicyAgency argues these five tryptamines "have no known medical use," setting up a showdown with the emerging psychedelics industry.

DEA Boosts Psychedelics Production (Again) to Meet Research Demand
PolicyDrug Enforcement Agency also addresses concerns from Native American Church regarding peyote poaching for mescaline research.

DEA Quadruples Psilocybin Manufacturing for Research in Final 2021 Production Quotas
PolicyDrug Enforcement Agency also hugely boosts MDMA and DMT quotas “in response to the nationwide public interest in hallucinogenic controlled substances research.”

DEA Proposes Huge Increase to Psilocybin and Psilocin Quotas for Research Purposes
PolicyIn its proposed revised 2021 quotas, the DEA suggests 4900% increase in the allowed quantities of psilocybin for research and clinical trial purposes.